Literature DB >> 19222487

Testicular dysgenesis syndrome: foetal origin of adult reproductive problems.

Christine Wohlfahrt-Veje1, Katharina M Main, Niels Erik Skakkebaek.   

Abstract

The evidence for the existence of testicular dysgenesis syndrome (TDS) is presented in this review. Several epidemiological studies have shown that conditions like cryptorchidism, impaired spermatogenesis, hypospadias and testicular cancer can be associated as risk factors for each other. Thus, the risk of testis cancer is significantly increased in men with cryptorchidism and/or infertility. Several recent studies point towards early dysgenesis of the foetal testis as the biological link between these disorders. Dysgenesis has been demonstrated in biopsies of the contralateral testis of men with testis cancer and in infertile men. The histological evidence includes immature seminiferous tubules with undifferentiated Sertoli cells, microliths and Sertoli-cell only tubules. Dysgenetic testes often have an irregular ultrasound pattern, where microliths may also be visible. Our current hypothesis is that maternal exposure to endocrine disrupting chemicals may contribute to the pathogenesis of TDS. Animal experiments have shown that all TDS symptoms, except testicular cancer, can be induced by foetal exposure to anti-androgenic chemicals. However, the cause of TDS in humans remains to be determined.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19222487     DOI: 10.1111/j.1365-2265.2009.03545.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  51 in total

1.  Endocrine disrupting chemicals: Multiple effects on testicular signaling and spermatogenesis.

Authors:  Bonnie Hy Yeung; Hin T Wan; Alice Ys Law; Chris Kc Wong
Journal:  Spermatogenesis       Date:  2011-07-01

2.  An update on phthalates and male reproductive development and function.

Authors:  Richard Grady; Sheela Sathyanarayana
Journal:  Curr Urol Rep       Date:  2012-08       Impact factor: 3.092

3.  Anthropometric, penile and testis measures in post-pubertal Italian males.

Authors:  C Foresta; A Garolla; A C Frigo; U Carraro; A M Isidori; A Lenzi; A Ferlin
Journal:  J Endocrinol Invest       Date:  2012-07-09       Impact factor: 4.256

Review 4.  Determination and stability of gonadal sex.

Authors:  David Schlessinger; José-Elias Garcia-Ortiz; Antonino Forabosco; Manuela Uda; Laura Crisponi; Emanuele Pelosi
Journal:  J Androl       Date:  2009-10-29

Review 5.  Sperm crisis: what crisis?

Authors:  Eberhard Nieschlag; Alexander Lerchl
Journal:  Asian J Androl       Date:  2012-09-24       Impact factor: 3.285

6.  Risk of childhood mortality in family members of men with poor semen quality.

Authors:  Heidi A Hanson; Erik N Mayer; Ross E Anderson; Kenneth I Aston; Douglas T Carrell; Justin Berger; William T Lowrance; Ken R Smith; James M Hotaling
Journal:  Hum Reprod       Date:  2016-12-06       Impact factor: 6.918

7.  Systematic reviews and meta-analyses of human and animal evidence of prenatal diethylhexyl phthalate exposure and changes in male anogenital distance.

Authors:  David C Dorman; Weihsueh Chiu; Barbara F Hales; Russ Hauser; Kamin J Johnson; Ellen Mantus; Susan Martel; Karen A Robinson; Andrew A Rooney; Ruthann Rudel; Sheela Sathyanarayana; Susan L Schantz; Katrina M Waters
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2018-09-10       Impact factor: 6.393

8.  Lifestyle behaviors associated with exposures to endocrine disruptors.

Authors:  Camille A Martina; Bernard Weiss; Shanna H Swan
Journal:  Neurotoxicology       Date:  2012-06-26       Impact factor: 4.294

Review 9.  Etiologic factors in testicular germ-cell tumors.

Authors:  Katherine A McGlynn; Michael B Cook
Journal:  Future Oncol       Date:  2009-11       Impact factor: 3.404

10.  Anogenital distance from birth to 2 years: a population study.

Authors:  Ajay Thankamony; Ken K Ong; David B Dunger; Carlo L Acerini; Ieuan A Hughes
Journal:  Environ Health Perspect       Date:  2009-07-13       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.